1. Cosnes J. Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. Best Pract Res Clin Gastroenterol 2004;18:481-96.

2. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, O'Morain CA, Gas-sull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colom-bel JF, Sahbatou M, Thomas G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.

3. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nunez G, Cho JH. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.

4. Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, Philpott DJ, Sansonetti PJ. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003;278:8869-72.

5. Mahida YR, Johal S. NF-kappa B may determine whether epithelial cell-microbial interactions in the intestine are hostile or friendly. Clin Exp Immunol 2001;123:347-9.

6. Elson CO, Cong Y, Brandwein S, Weaver CT, McCabe RP, Mahler M, Sundberg JP, Leiter EH. Experimental models to study molecular mechanisms underlying intestinal inflammation. Ann N Y Acad Sci 1998;859:85-95.

7. D'Haens GR, Geboes K, Peeters M, Baert F, Pen-ninckx F, Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998;114:262-7.

8. Marteau P, Lepage P, Mangin I, Suau A, Dore J, Pochart P, Seksik P. Review article: gut flora and inflammatory bowel disease. Aliment Pharmacol Ther 2004;20 Suppl 4:18-23.

9. Duchmann R, May E, Heike M, Knolle P, Neurath M, Meyer zum Buschenfelde KH. T cell specificity and cross reactivity towards enterobacteria, bacte-roides, bifidobacterium, and antigens from resident intestinal flora in humans. Gut 1999;44:812-18.

10. Marteau P, Seksik P, Lepage P, Dore J. Cellular and physiological effects of probiotics and prebiotics. Mini Rev Med Chem 2004;4:889-96.

11. Akira S, Hemmi H. TLR Signalling and the function of dendritic cells. Chem Immunol Allergy 2005;86:120-35.

12. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000;68:7010-17.

13. Shanahan F. The host-microbe interface within the gut. Best Pract Res Clin Gastroenterol 2002;16:915-31.

14. Gasche C, Scholmerich J, Brynskov J, D'Haens G, Hanauer SB, Irvine EJ, Jewell DP, Rachmilewitz D, Sachar DB, Sandborn WJ, Sutherland LR. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gas-troenterology, Vienna 1998. Inflamm Bowel Dis 2000;6:8-15.

15. Rutgeerts PJ. Conventional treatment of Crohn's disease: objectives and outcomes. Inflamm Bowel Dis 2001;7 Suppl 1:S2-S8.

16. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005;54:237-41.

17. Jess T, Winther KV, Munkholm P, Langholz E, Binder V. Mortality and causes of death in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Gastroenterology 2002;122:1808-14.

18. Hughes LE. Clinical classification of perianal Crohn's disease. Dis Colon Rectum 1992;35:928-32.

19. Linares L, Moreira LF, Andrews H, Allan RN, Alexander-Williams J, Keighley MR. Natural history and treatment of anorectal strictures complicating Crohn's disease. Br J Surg 1988;75:653-5.

20. Faucheron JL, Saint-Marc O, Guibert L, Parc R. Long-term seton drainage for high anal fistulas in Crohn's disease - a sphincter-saving operation? Dis Colon Rectum 1996;39:208-11.

21. Scott NA, Nair A, Hughes LE. Anovaginal and rec-tovaginal fistula in patients with Crohn's disease. Br J Surg 1992;79:1379-80.

22. Joseph M, Hewett PJ, Hill H. The use of setons in the management of complex enterocutaneous fistulae of the abdominal wall. Aust N Z J Surg 1994;64:628-9.

23. Williams JG, MacLeod CA, Rothenberger DA, Goldberg SM. Seton treatment of high anal fistulae. Br J Surg 1991;78:1159-61.

24. Jeshion WC, Larsen KL, Jawad AF, Piccoli DA, Verma R, Maller ES, Baldassano RN. Azathioprine and 6-mercaptopurine for the treatment of perianal Crohn's disease in children. J Clin Gastroenterol 2000;30:294-8.

25. Korelitz BI, Present DH. Favorable effect of 6-mer-captopurine on fistulae of Crohn's disease. Dig Dis Sci 1985;30:58-64.

26. Lecomte T, Contou JF, Beaugerie L, Carbonnel F, Cattan S, Gendre JP, Cosnes J. Predictive factors of response of perianal Crohn's disease to azathio-prine or 6-mercaptopurine. Dis Colon Rectum 2003;46:1469-75.

27. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340:1398-405.

28. Brown SC, Kazzazi N, Lord PH. Surgical treatment of perineal hidradenitis suppurativa with special reference to recognition of the perianal form. Br J Surg 1986;73:978-80.

29. Culp CE. Chronic hidradenitis suppurativa of the anal canal. A surgical skin disease. Dis Colon Rectum 1983;26:669-76.

30. Attanoos RL, Appleton MA, Hughes LE, Ansell ID, Douglas-Jones AG, Williams GT. Granulomatous hidradenitis suppurativa and cutaneous Crohn's disease. Histopathology 1993;23:111-15.

31. Burrows NP, Jones RR. Crohn's disease in association with hidradenitis suppurativa. Br J Dermatol 1992;126:523.

32. Ostlere LS, Langtry JA, Mortimer PS, Staughton RC. Hidradenitis suppurativa in Crohn's disease. Br J Dermatol 1991;125:384-6.

33. Roy MK, Appleton MA, Delicata RJ, Sharma AK, Williams GT, Carey PD. Probable association between hidradenitis suppurativa and Crohn's disease: significance of epithelioid granuloma. Br J Surg 1997;84:375-6.

34. Church JM, Fazio VW, Lavery IC, Oakley JR, Mil-som JW. The differential diagnosis and comorbidity of hidradenitis suppurativa and perianal Crohn's disease. Int J Colorectal Dis 1993;8:117-19.

35. Gower-Rousseau C, Maunoury V, Colombel JF, Coulom P, Piette F, Cortot A, Paris JC. Hidradenitis suppurativa and Crohn's disease in two families: a significant association? Am J Gastroenterol 1992;87:928.

36. Sheldon DG, Sawchuk LL, Kozarek RA, Thirlby RC. Twenty cases of peristomal pyoderma gangreno-sum: diagnostic implications and management. Arch Surg 2000;135:564-8; discussion 568-9.

37. Martinez F, Nos P, Benlloch S, Ponce J. Hidrad-enitis suppurativa and Crohn's disease: response to treatment with infliximab. Inflamm Bowel Dis 2001;7:323-6.

38. Katsanos KH, Christodoulou DK, Tsianos EV. Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn's disease patient. Am J Gastroenterol 2002;97:2155-6.

39. Bocchini SF, Habr-Gama A, Kiss DR, Imperiale AR, Araujo SE. Gluteal and perianal hidradenitis suppurativa: surgical treatment by wide excision. Dis Colon Rectum 2003;46:944-9.

40. Roussomoustakaki M, Dimoulios P, Chatzicos-tas C, Kritikos HD, Romanos J, Panayiotides JG, Kouroumalis EA. Hidradenitis suppurativa associated with Crohn's disease and spondyloarthropa-thy: response to anti-TNF therapy. J Gastroenterol 2003;38:1000-4.

41. Gupta AK, Skinner AR. A review of the use of infliximab to manage cutaneous dermatoses. J Cutan Med Surg 2004;8:77-89.

42. Rosi YL, Lowe L, Kang S. Treatment of hidrad-enitis suppurativa with infliximab in a patient with Crohn's disease. J Dermatolog Treat 2005;16:58-61.

Chapter 8



Luigi Naldi

How To Reduce Acne Scarring

How To Reduce Acne Scarring

Acne is a name that is famous in its own right, but for all of the wrong reasons. Most teenagers know, and dread, the very word, as it so prevalently wrecks havoc on their faces throughout their adolescent years.

Get My Free Ebook

Post a comment